Business Wire

RIDDLE&CODE

1.4.2022 10:17:06 CEST | Business Wire | Press release

Share
RIDDLE&CODE Energy Solutions GmbH appoints Kai Siefert as Managing Director

As of April 1, 2022 , Kai Siefert will take over the managing director position of the blockchain start-up RIDDLE&CODE Energy Solutions GmbH, a joint venture between Wien Energie GmbH, Austria's largest regional energy service provider, and blockchain scale-up RIDDLE&CODE GmbH, also based in Vienna.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005045/en/

Kai Siefert has 16 years of professional experience in the energy industry. In his previous position as IT strategist at Wien Energie GmbH, he led a team of software developers and electrical engineers from both joint venture partners to develop blockchain-based digital services and technical solutions for the renewable sector and its distributed energy sources. As a result of this work, the energy tokenisation platform "MyPower" was launched last summer, forming the core product of the young company. Wien Energie GmbH already uses this technology as part of its citizen solar power plant products, where the latest release includes a dynamic incentivisation and remuneration feature.

“Over the past four years, the team has built a digital framework for everyone to participate in decentralised energy markets,” says Siefert. “By using this framework, energy entrepreneurs are able to overcome even the toughest problems, such as asset aggregation and disaggregation, peer-to-peer energy marketing or certificate management. Based on our state-of-the-art tokenisation technology and digital wallets, we provide them with secure, transparent and highly scalable access to value chains of the green economy." As part of his new role, Siefert will focus on the internationalisation of the company and further development of the MyPower platform.

"We have proven the technical and commercial viability of energy tokenization in several "real-market projects" in Vienna. And there is great interest in the solution beyond the Austrian borders. As an immediate success of the whole RIDDLE&CODE Energy Solutions team, I am happy to announce the cooperation with the municipality of Stanz, the Austrian pioneer community of the EU-funded Smart Rural project, which was sealed earlier this week.", says Kai Siefert.

"Kai has done a great job with MyPower, driving strong growth, partnerships, and fantastic product innovation. His track record in the industry speaks for itself as well as his empathy for the challenges enterprises overcome while adopting blockchain technology," said Alexander Koppel, CEO at RIDDLE&CODE GmbH. "We are thrilled to have him as a managing director as we accelerate the next stage of growth."

About RIDDLE&CODE Energy Solutions GmbH

RIDDLE&CODE Energy Solutions GmbH provides blockchain-powered infrastructure that enables resilient, decentralised and fully decarbonized energy markets. With the development of the MyPower platform, the company has demonstrated an effective way for energy players into the machine economy. By tokenizing energy, machines and data, RIDDLE&CODE Energy Solutions GmbH significantly increases the liquidity of distributed assets making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.

More information about MyPower: www.riddleandcode.com/energy

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye